Search

Your search keyword '"immunotoxin"' showing total 201 results

Search Constraints

Start Over You searched for: Descriptor "immunotoxin" Remove constraint Descriptor: "immunotoxin" Publisher wiley Remove constraint Publisher: wiley
201 results on '"immunotoxin"'

Search Results

1. CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model

2. Development of a new minimally invasive phototherapy for lung cancer using antibody–toxin conjugate

Catalog

Books, media, physical & digital resources

3. Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma

4. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4+ Treg in nonhuman primates

5. Characterization of a re‐engineered, mesothelin‐targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

6. Fusion of apoptosis‐related protein Cytochrome c with anti‐HER‐2 single‐chain antibody targets the suppression of HER‐2+ breast cancer

7. Diphtheria‐toxin based anti‐human CCR4 immunotoxin for targeting human CCR4+ cells in vivo

8. Design and evaluation of a peptide‐based immunotoxin for breast cancer therapeutics

9. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR + cells

10. Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

11. Novel cucurmosin‐based immunotoxin targeting programmed cell death 1‐ligand 1 with high potency against human tumor in vitro and in vivo

12. Exploiting the internalization feature of an antibody against the glycosphingolipid SSEA‐4 to deliver immunotoxins in breast cancer cells

13. Expression and purification of soluble and functional fusion protein DAB389IL‐2 into theE. colistrain Rosetta‐gami (DE3)

14. Cytotoxic and apoptotic properties of a novel nano‐toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A

15. New treatment options in hairy cell leukemia with focus on BRAF inhibitors

17. Results from an international phase 2 study of the anti‐CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B‐lineage acute lymphoblastic leukemia

18. Correlation of abrin-mediated inhibition of protein synthesis and apoptosis

19. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4+ Treg in nonhuman primates

20. Monolith affinity chromatography for the rapid quantification of a single-chain variable fragment immunotoxin

21. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

23. A Perspective on the Effects of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors: A Mathematical Model Study

24. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein

25. Characterization of a re-engineered, mesothelin-targetedPseudomonasexotoxin fusion protein for lung cancer therapy

26. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations

27. Fully human MAP‐fusion protein selectively targets and eliminates proliferating CD64 + M1 macrophages

28. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia

30. P4‐022: MEMOGAIN REGULATES TAU PHOSPHORYLATION IN AN IMMUNOTOXIN MODEL OF CHOLINERGIC CELL LOSS

31. A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice

32. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia

33. PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a Tool for targeting Cancer Cells

34. Potential antitumor therapeutic application of <scp>G</scp> rimontia hollisae thermostable direct hemolysin mutants

35. Development and scale‐up of a commercial fed batch refolding process for an anti‐<scp>CD</scp>22 two chain immunotoxin

36. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

37. Ablation of Breast Cancer Cells Using Trastuzumab-Functionalized Multi-Walled Carbon Nanotubes and Trastuzumab-Diphtheria Toxin Conjugate

38. Production of anti-cancer immunotoxins in algae: Ribosome inactivating proteins as fusion partners

39. Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

40. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies

41. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

42. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

43. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues

44. Design of Targeted Protein Toxins

45. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

46. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma

47. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

48. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots

49. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model